Senores Pharmaceuticals Ltd reports Q2 FY27 revenue of ₹192.33 crore, up 24.9% year on year
- EBITDA was approximately ₹58 crore, with a 30.2% margin, up about 290 bps YoY; net profit rose 21.5% to ₹36.60 crore.
- The Board approved unaudited standalone and consolidated results and appointed Talati and Talati LLP as joint statutory auditors for FY27–FY31.
- Limited-review conclusions were unmodified; an emphasis of matter covered tax provisions and deferred tax based solely on management estimates.